Last updated 45 hours ago
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
192 patients around the world
Available in United States, Argentina
Shionogi
3Research sites
192Patients around the world
This study is for people with
Respiratory syncytial virus
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Participants who have new onset or worsening (if present chronically) of at least 1 of the following signs and/or symptoms consistent with a viral acute respiratory infection within 72 hours prior to randomization: fever, nasal congestion, nasal discharge, sore throat, cough, sputum production, shortness of breath, or wheezing.Participants diagnosed with RSV infection preferably using a rapid polymerase chain reaction (PCR) or other molecular-based diagnostic assay.Has at least 1 of the following risk factors for severe RSV disease.≥ 75 years of age.Chronic lung disease that is symptomatic and requiring chronic treatment.Chronic cardiovascular disease that is symptomatic and requiring chronic treatment.With the exception of the RSV disease, medically stable on the basis of medical history, physical examination, vital signs, and 12-lead electrocardiogram (ECG) performed at screening.
- Hospitalized or expected to be hospitalized within 24 hours of screening.Is considered by the investigator to be immunocompromised, due to an underlying medical condition or medical therapy, chemotherapy, radiation, stem cell or solid organ transplant.Has known allergies, hypersensitivity, or intolerance to S-337395 or to any of the excipients of the S-337395 or placebo formulation.Suspicion or known severe renal impairment.Any other medical or psychiatric condition making the participant unsuitable for the current study or interfering with the evaluation of response to the study intervention in the opinion of the investigator/subinvestigator.Has received a therapy intended to treat RSV infection within 14 days prior to screening.Is receiving chemotherapy or immunotherapy for malignancy.Has received RSV vaccination within 7 days prior to screening.Has had either confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or influenza infection (test was positive) during the 28 days prior to screening.Has any other confirmed clinically relevant respiratory infection by any pathogen at, or within 28 days of screening.
Sites
Clínica Mayo de UMCB SRL - Tucumán
Recruiting
Fundación Huésped - CABA
Recruiting
Instituto Médico Río Cuarto
Recruiting
SponsorShionogi
Study typeInterventional
Conditions
Respiratory syncytial virus
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07214571
